Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03637400 · ClinicalTrials.gov registry record · Phase 2
Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment
A Phase 2 study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 269
- Enrollment target
NCT03637400: Completed Phase 2 study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
NCT03637400 is a Phase 2 study that has completed, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 269 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (102% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03637400, a Phase 2 study, has completed, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 269 participants
- Enrollment target
Study Summary
The purpose of this study is to compare how well two different antibiotics, doxycycline (DOXY) and trimethoprim/sulfamethoxazole (TMP/SMX), work at curing uncomplicated skin and soft tissue infection (uSSTI) such as 1.Boils (pus in the skin, also known as abscesses and furuncles) or 2. Infections that appear only on the skin surface (called cellulitis and erysipelas) that have pus.
Primary Outcome
Clinical cure is the absence of clinical failure which is defined as occurrence of any one of the following events at ECR: * Fever (one or more temperature readings of ≥37.7°C between 48 and 72 hours); * Spread of lesion defined as an increase in size (length, width, or area) of the redness, edema, and/or induration such that the size of the lesion is greater than the size at baseline; * Administration of rescue antibacterial drug therapy or any non-trial antibacterial drug therapy for the trea
Interventions
- DRUG TMP-SMX
- DRUG DOXY
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2018-11-26 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 2 |
What the finished NCT03637400 record still lists
NCT03637400 is an interventional study that assigns participants to a tested intervention. The registered 269 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (102% higher).
The record links to 0 conditions, and to 2 interventions - of which TMP-SMX is the first listed.
NCT03637400 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03637400 about?
NCT03637400 is a clinical study titled "Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment". The purpose of this study is to compare how well two different antibiotics, doxycycline (DOXY) and trimethoprim/sulfamethoxazole (TMP/SMX), work at curing uncomplicated skin and soft tissue infection (uSSTI) such as 1.Boils (pus in the skin, also known as abscesses and furuncles) or 2. Infections th...
What is the current status of trial NCT03637400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 269 participants. The study started on 2018-11-26. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT03637400?
The interventions under investigation include: TMP-SMX (DRUG), DOXY (DRUG).
Who is sponsoring clinical trial NCT03637400?
This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03637400's enrollment target sits among peer trials
269 208th of 2000 higher than 1,793 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04802291 · 269 participants · NA
HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity
- NCT06500455 · 269 participants · Phase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
- NCT06630676 · 269 participants · NA
The Ability of Chronic Pain Patients to Self-diagnose Their Chief Source of Low Back Pain
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI